(Adnkronos) - “E’ una terapia salvavita e conferma l’impegno quarantennale di Pierre Fabre Pharma in oncoematologia”. “ed ha come focus migliorare areee terapeutiche con un grosso impatto sociale. In particolare attualmente siamo impegnati nel melanoma e nel tumore del colon retto. Ma avremo delle novità; una nuova terapia per il tumore del polmone non a piccole cellule e per la vescica iperattiva”.
Category
🗞
NewsTranscript
00:00Having obtained the reimbursement for the first allogenic cell therapy to treat the PTLD disease,
00:13post-traumatic lymphoclonal disease, positive to the Hextenbar virus, is a great source of pride.
00:20In particular, this is a disease that affects a few patients who have undergone a transplant,
00:26despite the fact that the Hextenbar virus is very widespread in the world population, about 90-95%.
00:35This new therapy is nothing more than demonstrating the commitment of Pierre Fabre in the oncological area,
00:44which has lasted for more than 40 years.
00:46Pierre Fabre is committed to various therapeutic areas and his focus is to improve therapeutic areas
00:53with a large social impact.
00:55In particular, we are currently committed to melanoma, rectal tumor, but we will have some news.
01:03In particular, we will have a new therapy for the lung tumor, not in small cells,
01:10which remains one of the big killers among tumors, and another therapy for hyperactive vesicles.
01:17Hyperactive vesicles are a pathology that does not put the patient's life at risk,
01:22but has a large social impact on their quality of life.
01:25We think that in Italy, 16.6% of the population over the age of 40 suffers from it.
01:33We are therefore sure that these two new therapeutic options bring advantages to patients.
01:41The advantages brought by the first cell allogeneic therapy are important because it is a life-saving therapy.
01:50In particular, in a therapeutic area in which patients do not have many therapeutic options.
01:58In fact, as the ALLELE registrative study shows, this therapy is effective and safe.
02:05We keep in mind that both pediatric and adult patients who have had or suffered a lung tumor
02:17and have a solid organ such as the heart, lungs, kidneys, but also the spleen,
02:27are treated with this allogeneic therapy.
02:30This is why we are really happy to provide Italian doctors with this first allogeneic therapy
02:38for patients who suffer from post-tumor proliferative lymphoma,
02:44who have tested positive for the virus in September and who have not responded to first-line therapies.